Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Kamada Ltd. (NASDAQ:KMDA) stock picked up as the company announced receiving the FDA approval for KEDRAB, its rabies immune globulin. The drug is expected to launched in the US in early 2018. Under the terms of its agreement with Kedrion Biopharma, Kamada holds the license for KEDRAB, and Kedrion Biopharma has exclusive rights to commercialize the product in the U.S. With the approval, Kedrion Biopharma expands its portfolio of immune globulin products, which includes RhoGAM and GAMMAKED. This is the second FDA approved product for Kamada.

The stock gained over 16 percent in its pre-market trading session.

Biogen ($BIIB) announced receiving the European Commission’s approval for IMRALDI. The product is a biosimilar referencing AbbVie's HUMIRA (adalimumab). It is the third European Commission approval for "biosimilar" versions from the joint venture, Samsung Bioepis, of drugs in a class known as TNF inhibitors. The drug was approved for a number of indications including psoriatic arthritis, Crohn's disease, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa and ulcerative colitis.
The company stock reacted positively to the news. Biogen stock is flat on Year to Date basis.


LabCorp ($LH) announced receiving the antitrust approval for its $1.2 billion acquisition of Chiltern International Group. The groups were granted early termination of the Hart Scott Rodino waiting period by the FTC.

Titan Pharmaceuticals ($TTNP) announced receiving the FDA approval of Investigational New Drug (IND) application for its ropinirole implant intended for treatment of the signs and symptoms of Parkinson's disease. A Phase 1/2 clinical study with about 20 patients will start shortly.

Tandem Diabetes Care ($TNDM) announced the grant of a new patent by the USPTO. The new patent no. 9,737,656 is related to the use of a software application operating on a remote consumer electronic device to initiate, program and deliver a medicament bolus to a patient using a medical infusion pump. The patent will remain in effect until 2035.
Adamas Pharmaceuticals ($ADMS) announced receiving the FDA approval for its GOCOVRI extended-release capsules for the treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa-based therapy, with or without concomitant dopaminergic medications. The company plans to commercially launch the product in January 2018.


Novartis ($NVS) announced inking a deal with Xoma for global commercial rights to gevokizumab, an anti-IL-1 beta allosteric monoclonal antibody, for the potential treatment of a range of inflammatory diseases. Novartis has also signed a separate contract with regard to a license to intellectual property covering the use of IL-1 beta-targeting antibodies to treat cardiovascular disease.
Cesca Therapeutics ($KOOL) announced inking an agreement with Boyalife WSN Ltd., a Hong Kong based firm. The deal pertains to the distribution of its biobanking and point-of-care solutions in China, India, Singapore and the Philippines. The companies did not disclose the financial terms of the deal.

Brokerage Action Company Rating Price Target Impact on Share Price Actions
Cowen and Company Reiterates Adamas Pharmaceuticals (ADMS)
Outperform $45.00 -> $55.00 N/A
KeyCorp Reiterates AngioDynamics (ANGO)
Hold Low

KeyCorp Reiterates CONMED Corporation (CNMD)
Hold Low

HC Wainwright Reiterates Edap Tms S.A. (EDAP)
Buy $7.00 Low

HC Wainwright Initiates Jazz Pharmaceuticals PLC (JAZZ)
Neutral $144.00 Low

SunTrust Banks Initiates Nabriva Therapeutics AG (NBRV)
Buy Low

Gainers (% price change)Last TradeChangeMkt CapChina Cord Blood CorpCO14.07+1.58 (12.65%)1.70BImmunomedics, Inc.IMMU10.68+0.96 (9.88%)1.19BBioCryst PharmaceuticalsBCRX4.83+0.41 (9.28%)388.47MNewLink Genetics CorpNLNK7.08+0.52 (7.93%)208.30MGTx, Inc.GTXI6.51+0.46 (7.60%)104.54MLosers (% price change)Acadia Healthcare Co. IncACHC45.55-1.88 (-3.96%)4.00BAlere IncALR47.50-1.89 (-3.83%)4.16BPsychemedics Corp.PMD20.78-0.73 (-3.39%)114.11MCorVel CorporationCRVL49.90-1.35 (-2.63%)935.91MABIOMED, Inc.ABMD148.93-3.97 (-2.60%)6.57BMost Actives (dollar volume)Johnson & JohnsonJNJ132.89+0.09 (0.07%)356.68BMerck & Co., Inc.MRK62.71+0.56 (0.90%)171.03BPfizer Inc.PFE33.23-0.01 (-0.03%)197.89BTeva PharmaceuticalTEVA16.36-0.13 (-0.79%)16.77BUnitedHealth Group IncUNH194.75+0.51 (0.26%)188.30B